DelveInsight’s ESR1 Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the ESR1 Mutated Metastatic Breast Cancer Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The ESR1 Mutated Metastatic Breast Cancer Market report covers emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
ESR1 Mutated Metastatic Breast Cancer: Overview
Metastatic breast cancer is essentially a Stage IV breast cancer wherein cancer originates in breast tissue and then spreads to other body parts. The steroid hormone, estradiol, plays a vital role in breast cancer progression, and a majority of human breast cancers start as estrogen-dependent and express the estrogen receptor (ER). ERα is the major ER subtype in the mammary epithelium and plays a critical role in mammary gland biology and breast cancer progression.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market
Some of the key facts of the ESR1 Mutated Metastatic Breast Cancer Market Report
According to DelveInsight, in 2020, it is estimated that the total diagnosed prevalent cases of HR-positive breast cancer in the 7MM were 1,158,467. It was noted that among diagnosed prevalent cases of HR-positive breast cancer in the 7MM, the maximum number of cases were occupied by the United States (494,584), in 2020.
In the 7MM, the diagnosed prevalent cases of metastatic breast cancer were 341,748 in 2020. That also includes early-stage cases which progressed to metastatic stage.
In 2020, the diagnosed prevalent cases of metastatic breast cancer in the US were 145,902, these cases also included early-stage cases which progressed to metastatic. The diagnosed prevalent metastatic breast cancer cases are likely to increase by 2030 at a CAGR of 2.17%.
ESR1 Mutated Metastatic Breast Cancer Market
The ESR1 Mutated Metastatic Breast Cancer Market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the ESR1 Mutated Metastatic Breast Cancer Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted ESR1 Mutated Metastatic Breast Cancer Market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the ESR1 Mutated Metastatic Breast Cancer Market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
ESR1 Mutated Metastatic Breast Cancer Market Outlook
ESR1 mutations have increased over time, even with AI therapy, indicating their adaptability to AI therapeutic conditions. In addition, the presence of ESR1 mutations has been correlated with a shorter time to treatment failure, as MBC patients with ESR1 mutations exhibit an inadequate response to and shorter duration of effective endocrine control.
United States contributes to the major share of the ESR1 Mutated Metastatic Breast Cancer market as compared to other countries, such as EU5 (Italy, Spain, United Kingdom, France, and Germany) and Japan. Preclinical and clinical studies have demonstrated that ESR1 mutations can preexist in primary tumors and can be enriched during metastasis. Furthermore, ESR1 mutations express a unique transcriptional profile that favors tumor progression, suggesting that selected ESR1 mutations may influence metastasis.
ESR1 Mutated Metastatic Breast Cancer Diagnosis
At the time of diagnosis, tumor tissue and baseline liquid biopsies could be used for mutation detection using sensitive next-generation sequencing or MPS. Following neoadjuvant therapy, ddPCR could be employed to confirm ESR1 mutations. ddPCR could also be used to monitor mutation status during hormone therapy via blood sampling during standard follow-up visits. These liquid biopsies could also be used to monitor emerging driver mutations and subclonal evolution during therapy which would affect hormone therapy sequencing and enable precision therapy on an individual basis. Plasma sample (ctDNA) and ddPCR technology are new and reliable for the determination of ESR1 mutation.
ESR1 Mutated Metastatic Breast Cancer Epidemiology
The epidemiology section covers insights into the historical and current ESR1 Mutated Metastatic Breast Cancer Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
ESR1 Mutated Metastatic Breast Cancer Market Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ESR1 Mutated Metastatic Breast Cancer Market or expected to get launched in the market during the study period. The analysis covers ESR1 Mutated Metastatic Breast Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the ESR1 Mutated Metastatic Breast Cancer Market Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies. Unmet needs in the Kaposi’s sarcoma include therapies that are oral, anthracycline sparing, and deliverable in resource-limited settings. Another major unmet need is the relapse and refractory cases in the patients given treatment with Doxil.
Elacestrant (RAD1901): Radius Pharmaceuticals/Berlin-Chemie (Menarini Group)
Radius Pharmaceutical’s elacestrant is a selective estrogen receptor degrader (SERD) out-licensed to Menarini Group, which is being evaluated for potential use as a once-daily oral treatment for HR+ breast cancer. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. The Phase III trial EMERALD with Radius’ partner Menarini Group is on track for topline results readout during the second half of 2021.
Amcenestrant (SAR439859): Sanofi
Sanofi’s Amcenestrant (formerly known as SAR439859) is an investigational oral selective estrogen receptor degrader (SERD) dosed once daily. It antagonizes and degrades the estrogen receptor (ER), in turn blocking the ER signaling pathway. Amcenestrant is a potent, oral selective estrogen receptor α-(ERα) degrader, dosed once daily. The drugs have received FDA fast-track designation. In February 2020, Sanofi announced that it intends to submit a regulatory application for metastatic or locally advanced breast cancer, progressing after previous hormonal therapies in 2021.
Rintodestrant (G1T48): G1 Therapeutics, Inc.
G1 is advancing one novel therapy for people living with cancer. Rintodestrant is an oral selective estrogen receptor degrader (SERD), which is being developed as a monotherapy and combined with a CDK4/6 inhibitor, Ibrance (palbociclib), for the treatment of ER+ HER2− breast cancer. The company will evaluate partnering options for rintodestrant following data read-out from the combination study with palbociclib. The drug is currently being evaluated in phase I/IIa (dose escalation/dose expansion) clinical trial in ER+, HER2− breast cancer. The company recently announced Phase II results.
ESR1 Mutated Metastatic Breast Cancer Market Companies
Roche, and Others
Giredestrant (RG6171, GDC-9545)
OP1250, and Others
Table of content
Competitive Intelligence Analysis
Market Overview at a Glance
Disease Background and Overview
Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Key Endpoints of ESR1 Mutated Metastatic Breast Cancer Market Treatment
Seven Major Market Analysis
7MM: Market Outlook
Access and Reimbursement Overview
Consult with our Business Expert @ https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States